1448032185
Treating Blood Cancers

Advertise on podcast: Treating Blood Cancers

Rating
★★★★★
4.8
from
12 reviews
This podcast has
98 episodes
Language
English
Explicit
No
Date created
2018/12/28
Latest episode
2026/01/23
Average duration
37 min.
Release period
23 days

Description

Podcast Series for Professionals by Blood Cancer United

Unlock Treating Blood Cancers podcast Email contact info,
Listeners & Audience details

Email contact information

Direct podcast contact details

Listeners

Audience numbers & engagement insights

Audience details

Podcast Insights

Podcast episodes

Check latest episodes from Treating Blood Cancers podcast


Building Resilience: Burnout & Compassion Fatigue Tools for HCPs
2026/01/23
Chelsey Winegar, LCSW, MBA, Intermountain Health, Murray, UT Recorded on January 8, 2026 Chelsey Winegar, LCSW, MBA Manager of Oncology Services Intermountain Health Murray, UT Join Chelsey Winegar, LCSW and Manager of Oncology Services at Intermountain Health in Murray, UT, as she breaks down the key differences between burnout and compassion fatigue, and why understanding both is essential for the well being of healthcare professionals and the patients they serve. Chelsey shares practical strategies for recognizing early warning signs, monitoring staff wellness, and building supportive, stigma free environments. The episode also highlights resources and education to help clinicians maintain resilience in demanding clinical settings. Listen in to learn more today! Mentioned on this episode: Trauma Stewardship Additional Blood Cancer United Resources: Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education Blood Cancer United Resources for Patients
Key Insights from Attending ASH 2025
2026/01/13
Lore Gruenbaum, PhD, Blood Cancer United, Washington, DC Recorded on December 18, 2025 Lore Gruenbaum, PhD Chief Scientific Officer & Senior Vice President of Research Blood Cancer United Washington, DC Join Dr. Lore Gruenbaum, Chief Scientific Officer and Senior Vice President of Research at Blood Cancer United, to provide practice-changing data in hematologic malignancies from the 67th American Society of Hematology (ASH) Annual Meeting. Explored are breakthroughs in multiple myeloma, AML, CLL, and advances in cell therapy. Discussion also covers the growing use of artificial intelligence to accelerate precision medicine, spotlighting the Blood Cancer United Beat AML® Master Clinical Trial as a model for AI-driven trial design and real-time clinical decision-making. Tune in today for the key takeaways you need to know! Additional Blood Cancer United Resources: Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education Blood Cancer United Resources for Patients
Delivering Equitable Cancer Care: What Every Healthcare Professional Should Know
2025/12/17
Raymond Mailhot, MD, MPH, University of Miami, Miami, FL Recorded on December 2, 2025 Raymond Mailhot, MD, MPH Department of Radiation Oncology University of Miami Miami, FL Join us with Dr. Raymond Mailhot from the University of Miami as we explore how social determinants of health shape patient experiences, treatment decisions, and outcomes. He discusses the importance of cultural competence in delivering equitable, patient-centered care and shares practical communication strategies to better engage patients and collaborate effectively. This episode offers actionable insights to strengthen relationships and improve overall care quality. Tune in today to gain practical strategies that will enhance your approach to patient-centered care and drive better outcomes! Additional Blood Cancer United Resources: Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education Blood Cancer United Medical Debt Case Management Program for Patients Blood Cancer United Additional Resources for Patients
Hairy Cell Leukemia: Strategies for Improved Patient Outcomes
2025/11/20
Paul J. Hampel, MD, Mayo Clinic, Rochester, MN Recorded on November 4, 2025 Paul J. Hampel, MD Assistant Professor of Medicine Division of Hematology, Department of Medicine Mayo Clinic Rochester, MN In this episode, Dr. Paul Hampel from Mayo Clinic Rochester takes a comprehensive look at hairy cell leukemia (HCL). He reviews the current diagnostic work-up, including immunophenotypic and molecular testing, and highlights key clinical features that distinguish HCL from related disorders. Dr. Hampel also discusses approved frontline therapies and evidence-based approaches for relapsed or refractory disease, with attention to infection risk and supportive care. The conversation explores emerging agents, novel combinations, and clinical trials shaping the next wave of HCL management. Join us for this expert discussion, offering practical insights to enhance care and outcomes for patients with HCL.
Managing CML: What HCPs Need to Know
2025/11/06
Michael J. Mauro, MD, Memorial Sloan Kettering Cancer Center, New York, NY Recorded on October 23, 2025 Michael J. Mauro, MD Director, Chronic Myeloid Leukemia Program Professor of Medicine, Leukemia Service Memorial Sloan Kettering Cancer Center New York, NY Tune in for this expert-led discussion with Dr. Michael Mauro from Memorial Sloan Kettering Cancer Center on the evolving management of chronic myeloid leukemia (CML) in the era of tyrosine kinase inhibitors (TKIs) and newly approved FDA therapies. Dr. Mauro explores how TKIs have transformed prognosis, key factors guiding initial therapy selection, and best practices for managing treatment-related side effects. He also shares updates on TKI discontinuation criteria, long-term monitoring, and a forward look at ongoing trials and emerging therapeutic advances shaping the future of CML care. Gain actionable insights to enhance patient outcomes today!
Understanding MRD: Insights for clinical practice and patient care
2025/10/10
Rahul Banerjee, MD, FACP, Fred Hutchinson Cancer Center, Seattle, WA Recorded on September 25, 2025 Rahul Banerjee, MD, FACP Assistant Professor Fred Hutchinson Cancer Center Seattle, WA In this episode, Dr. Rahul Banerjee from Fred Hutchinson Cancer Center in Seattle, WA, discusses the evolving role of measurable residual disease (MRD) in hematologic malignancies. He explores what MRD is, how assays are used and interpreted, and its impact across the disease continuum. The conversation also covers MRD’s role in clinical trials, how to effectively explain MRD to patients, practical considerations for testing in community settings, and key education resources for both healthcare professionals and patients. Tune in today to gain practical insights you can apply in your daily practice! This episode is supported by Adaptive Biotechnologies Corporation and Allogene Therapeutics.
Pediatric Acute Leukemias: Focus on clinical trials for treatment
2025/09/19
Ann Collins, PA, Blood Cancer United, Washington, DC, Kelly Laschinger, MSN, RN, CPNP, CPHON, Blood Cancer United, Washington, DC, Sarah K. Tasian, MD, Children’s Hospital of Philadelphia, Philadelphia, PA Recorded on September 9, 2025 Ann Collins, PA Project Leader, Pediatric Acute Leukemia Master Clinical Trial (PedAL) Blood Cancer United Washington, DC Kelly Laschinger, MSN, RN, CPNP, CPHON Director, Clinical Trial Support Center Blood Cancer United Washington, DC Sarah K. Tasian, MD Blood Cancer United PedAL Master Clinical Trial Lead Associate Professor of Pediatrics, University of Pennsylvania School of Medicine Chief of Hematologic Malignancies Program, Children’s Hospital of Philadelphia Philadelphia, PA Join us for our first episode as Blood Cancer United! In this episode, Dr. Sarah Tasian, from Children’s Hospital of Philadelphia, and Ann Collins and Kelly Laschinger, from Blood Cancer United, join us for an in-depth discussion on pediatric acute leukemias. The conversation delves into the latest therapies, treatment challenges, and the complex realities of long-term survivorship. We also explore the groundbreaking Blood Cancer United Pediatric Acute Leukemia Master Clinical Trial (PedAL), its bold vision, global collaboration, and unified approach to data collection. Valuable clinical trial resources and strategies to support patients, families, and healthcare professionals are also shared. Tune in today!
Charting the Course of ALL: From Diagnosis to Advances
2025/07/09
Catherine Lai, MD, MPH, University of Pennsylvania Perelman Center for Advanced Medicine, Philadelphia, PA Recorded on June 27, 2025 Catherine Lai, MD, MPH Associate Professor Physician Leader, Leukemia Clinical Research Unit University of Pennsylvania Perelman Center for Advanced Medicine Philadelphia, PA In this episode, Dr. Catherine Lai, from the University of Pennsylvania’s Perelman Center for Advanced Medicine, joins us to discuss the current landscape of adult acute lymphoblastic leukemia (ALL) treatment. She highlights recent advances in frontline and relapsed therapies, the critical role of measurable residual disease (MRD), and the use of immunotherapy and targeted treatments. Dr. Lai further explores transplant considerations, management of side effects, and tailored approaches for B-cell and T-cell ALL. She also emphasizes patient-centered care, including strategies for end-of-life discussions and shared decision-making. Tune in today for expert insights and practical takeaways on the evolving future of ALL care!
Strategies and Advances in AML
2025/06/12
Uma Borate, MBBS, MS, The Ohio State University, Columbus, OH Recorded on May 27, 2025 Uma Borate, MBBS, MS Associate Professor, Division of Hematology Acute Leukemia Clinical Research Disease Group Leader The Ohio State University Columbus, OH What’s changing in acute myeloid leukemia (AML)? Join Dr. Uma Borate from The Ohio State University in Columbus, Ohio, as she dives into emerging breakthroughs in AML biology, including molecular drivers, menin inhibitors, and the challenges of developing bispecifics and CAR T-cell therapies. She also shares updates from the LLS Beat AML® Master Clinical Trial and ongoing clinical trials, and reflects on the evolving treatment landscape across age groups. Don’t miss this dynamic conversation packed with expertise and hope for the future of AML!
Advancing Care in Myeloproliferative Neoplasms (MPNs)
2025/05/29
Aaron Gerds, MD, MS, Cleveland Clinic, Cleveland, OH Recorded on May 13, 2025 Aaron Gerds, MD, MS Associate Professor of Medicine Cleveland Clinic Lerner College of Medicine Case Western Reserve University School of Medicine Medical Director Case Comprehensive Cancer Center Clinical Research Office Cleveland, OH In this episode, Dr. Aaron Gerds from the Cleveland Clinic explores the intricacies of Myeloproliferative Neoplasms (MPNs), from diagnosis and monitoring to treatment goals and the latest therapeutic advances. Dr. Gerds discusses emerging therapies, the significance of clinical trials, strategies for managing side effects and long-term effects, and valuable resources for healthcare professionals, patients, and families. Tune in today for expert insights on MPNs! This episode is supported by GSK plc and Karyopharm Therapeutics.
A Collaborative Approach to Survivorship Care
2025/05/13
A Collaborative Approach to Survivorship Care Tessa Faye Flores, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY … A Collaborative Approach to Survivorship CareRead More »
MDS: Patient-Centered Approaches to Diagnosis and Treatment
2025/04/30
Mikkael A. Sekeres, MD, MS, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL Recorded on April 17, 2025 Mikkael A. Sekeres, MD, MS Chief, Division of Hematology Professor of Medicine Sylvester Comprehensive Cancer Center University of Miami Miami, FL Join us with Dr. Mikkael Sekeres of the University of Miami Sylvester Comprehensive Cancer Center as he explores the complexities of diagnosing and treating Myelodysplastic Syndromes (MDS), including “watch and wait.” Through case-based discussion, he highlights advances in high-risk MDS management, from novel targeted therapies to stem cell transplantation and clinical trials. Dr. Sekeres also shares strategies for managing side effects and emphasizes the importance of multidisciplinary care in improving patient outcomes. Tune in to gain valuable insights on MDS today!
Optimizing Care for Pediatric Blood Cancer
2025/04/18
Jeffrey Magee, MD, PhD, Washington University School of Medicine, St. Louis, MO Recorded on April 3, 2025 Jeffrey Magee, MD, PhD Elizabeth H. and James S. McDonnell III Professor of Pediatrics Director, McDonnell Pediatric Cancer Center Division of Pediatric Hematology and Oncology Washington University School of Medicine St. Louis, MO In this episode, we sit down with Dr. Jeffrey Magee from the McDonald Pediatric Cancer Center at the Washington University School of Medicine in St. Louis to discuss the evolving landscape of pediatric blood cancers. Reflecting on his work, Dr. Magee shares, “One of the things I really love about the job is that it operates right at the interface between the science and the professional practice of medicine.” He examines groundbreaking advances bringing new hope to children and their families, from novel therapies and CAR T-cell therapy to the crucial role of clinical trials. Dr. Magee also speaks candidly about the challenges of delivering difficult news and shares compassionate strategies for supporting families through their toughest moments. Join us for this insightful and informative conversation on the future of pediatric blood cancer care today! Additional LLS Resource: Stars Will Twinkle, The Sun Will Shine A three-book series and movie for kids with blood cancer. Follow Olivia and her family as she is diagnosed with leukemia, goes to the hospital for treatment, and returns to school.
Navigating Complex and Challenging Cases in Myeloma
2025/03/28
Angela Dispenzieri, MD, Mayo Clinic, Rochester, MN Recorded on March 18, 2025 Angela Dispenzieri, MD Consultant, Division of Hematology Serene M. and Frances C. Durling Professor of Medicine and of Laboratory Medicine and Pathology Mayo Clinic Rochester, MN Join us as we dive into in the complex care of amyloid and myeloma with Dr. Angela Dispenzieri from Mayo Clinic Rochester, Minnesota. She explains the diagnosis and explores the differences between amyloid and myeloma. Discussion on treatment strategies for complex cases, side effects of therapies, and difficult conversations with patients, provide practical information on patient care. Tune in today to learn more about the complexities of myeloma. This episode is supported by GSK plc.
Beyond Burnout: Strategies for Empowering Healthcare Professionals
2025/03/13
Guy Maytal, MD, Forge Health and Weill Cornell Medicine, New York Recorded on February 20, 2025 Guy Maytal, MD Chief Medical Officer, Forge Health White Plains, NY Clinical Assistant Professor of Psychiatry, Weill Cornell Medicine New York, NY In this episode, Dr. Guy Maytal, from Forge Health and Weill Cornell Medicine in New York, explores burnout and wellness in healthcare professionals, highlighting the difference between burnout and compassion fatigue. He shares valuable insights on recognizing these issues, while emphasizing the importance of connection, resilience, and self-care in preventing and overcoming burnout. Dr. Maytal also offers practical strategies for institutions to better support healthcare professionals. Tune in for the latest insights on healthcare professional wellness today!

Podcast reviews

Read Treating Blood Cancers podcast reviews


4.8 out of 5
12 reviews
★★★★★
Ms.Vader 2021/03/25
Lymphoma lesbian thanks you!
This was very comforting and informative. Wyoming isn’t the easiest place to get sensitive LGBTQI care. But we are doing ok so far. Blessings on your ...
check all reviews on apple podcasts

Podcast sponsorship advertising

Start advertising on Treating Blood Cancers relevant audience podcasts


What do you want to promote?